Department of Cardiology, Heart and Diabetes Centre NRW, Ruhr University Bochum, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany.
Thorax. 2011 May;66(5):402-7. doi: 10.1136/thx.2010.146522. Epub 2011 Mar 10.
Sleep disordered breathing is common and of prognostic significance in patients with congestive heart failure (CHF). Complex sleep apnoea (complexSA) is defined as the emergence of central sleep apnoea during continuous positive airway pressure (CPAP) treatment in patients with obstructive sleep apnoea (OSA). This study aims to determine the prevalence and predictors for complexSA in patients with CHF with OSA, and to assess the effects of treatment with adaptive servoventilation.
192 patients with CHF (left ventricular ejection fraction (LVEF) ≤45%, New York Heart Association (NYHA) class ≥2) and OSA (apnoea-hypopnoea index (AHI) ≥15) were investigated using echocardiography, cardiopulmonary exercise testing, measurement of hyperoxic, hypercapnic ventilatory response, 6 min walk test and measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP) prior to CPAP introduction. If patients demonstrated complexSA (AHI >15/h with <10% obstructive events) during CPAP titration, adaptive servoventilation was introduced and the investigations were repeated at 3 monthly follow-up visits.
ComplexSA developed in 34 patients (18%) during CPAP titration. After adjustment for demographic and cardiac parameters, measures of CO(2) sensitivity (higher hyperoxic, hypercapnic ventilatory response) were independently associated with complexSA. Patients using adaptive servoventilation had improved AHI, NYHA class, NT-proBNP concentration, LVEF, hyperoxic, hypercapnic ventilatory response, oxygen uptake during cardiopulmonary exercise testing and the relationship between minute ventilation and the rate of CO(2) elimination (VE/Vco(2) slope) at last individual follow-up (14±4 months).
There is a high prevalence of complexSA in patients with OSA and CHF, and those who develop complexSA have evidence of higher respiratory controller gain before application of CPAP. Treatment with adaptive servoventilation effectively suppressed complexSA and had positive effects on cardiac function and respiratory stability.
睡眠呼吸障碍在充血性心力衰竭(CHF)患者中很常见,具有预后意义。复杂睡眠呼吸暂停(complexSA)定义为阻塞性睡眠呼吸暂停(OSA)患者在持续气道正压通气(CPAP)治疗中出现中枢性睡眠呼吸暂停。本研究旨在确定 CHF 合并 OSA 患者中 complexSA 的患病率和预测因素,并评估适应性伺服通气治疗的效果。
192 例 CHF 患者(左心室射血分数(LVEF)≤45%,纽约心脏协会(NYHA)分级≥2)和 OSA(呼吸暂停-低通气指数(AHI)≥15)接受超声心动图、心肺运动试验、高氧、高碳酸通气反应测量、6 分钟步行试验和 N 端脑利钠肽前体(NT-proBNP)测量,然后进行 CPAP 导入。如果患者在 CPAP 滴定过程中出现 complexSA(AHI>15/h,阻塞性事件<10%),则引入适应性伺服通气,并在 3 个月随访时重复这些检查。
34 例(18%)患者在 CPAP 滴定过程中出现 complexSA。在调整人口统计学和心脏参数后,CO2 敏感性测量(更高的高氧、高碳酸通气反应)与 complexSA 独立相关。使用适应性伺服通气的患者 AHI、NYHA 分级、NT-proBNP 浓度、LVEF、高氧、高碳酸通气反应、心肺运动试验期间摄氧量以及分钟通气量与 CO2 消除率之间的关系(VE/Vco2 斜率)在最后一次个体随访时(14±4 个月)得到改善。
OSA 和 CHF 患者中 complexSA 的患病率较高,出现 complexSA 的患者在应用 CPAP 前呼吸控制器增益较高。适应性伺服通气治疗有效抑制了 complexSA,并对心功能和呼吸稳定性产生了积极影响。